Ali Taghizadehghalehjoughi1*, Sidika Genc2, Yesim Yeni2, David R Wallace3, Ahmet Hacimuftuoglu2 and Zeynep Cakir4
1Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, Ataturk University, Erzurum, Turkey
2Faculty of Medicine, Department of Medical Pharmacology, Ataturk University, Erzurum, Turkey
3Oklahoma State University Center for Health Sciences, School of Biomedical Sciences, Tulsa, Oklahoma, United States
4Faculty of Medicine, Department of Emergency Medicine, Ataturk University, Erzurum, Turkey
*Corresponding Author: Ali Taghizadehghalehjoughi, Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, Ataturk University, Erzurum, Turkey.
Received: October 07, 2020; Published: November 30, 2020
Prostate and colorectal cancer are among the most common malignant tumors. The aim of the current study is to evaluate the effects of melatonin (MLT) and pycnogenol (PYG) combination on PC-3 and HT-29 cancer lines and to address the question of where or not MLT increases PYG antitumor effect in the PC-3 and HT-29 cancer lines. The combination of 100 μg/ml PYG + 40 μg/ml MLT reduced cell viability in both HT-29 and PC-3 cells (66 and 65%, respectively). Results from the TAC, TOS and LDH assays were correlated to our MTT results. In addition, the cellular migration test showed that the wound line was widened in the combination groups starting at 72 hours compared to the other groups. Cisplatin has routinely used as an anticancer agent, but because of side effects, usage is limitation. The combination of 40 μg/ml MLT with PYG increased the extent of antitumor effects compared to Cisplatin and reduced the cell viability effectively than Cisplatin. The combination of MLT + PYG shows promise to be a new anticancer agent for the treatment of HT-29 and PC-3 patients or adjuvant for the reduction of the side effects of chemotherapeutics.
Keywords: HT-29; Melatonin; PC-3; Pycnogenol
Citation: Ali Taghizadehghalehjoughi., et al. “Combination of Pycnogenol and Melatonin Reduce PC-3 and HT29 Cell Migration: Comparison to the Actions of Cisplatin". Acta Scientific Pharmaceutical Sciences 4.12 (2020): 176-188.
Copyright: © 2020 Ali Taghizadehghalehjoughi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.